Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prothena Corp PLC

4.77
-0.0600-1.24%
Volume:678.59K
Turnover:3.23M
Market Cap:256.75M
PE:-2.33
High:4.88
Open:4.83
Low:4.66
Close:4.83
Loading ...

Buy/Sell: Wall Street's Top 10 Stock Calls This Week

The Fly
·
01 Jun

Prothena Cut to Underperform From Neutral by B of A Securities

Dow Jones
·
29 May

Prothena Corporation Plc : Bofa Global Research Cuts to Underperform From Neutral; Cuts Price Objective to $4 From $22

THOMSON REUTERS
·
28 May

BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target

MT Newswires Live
·
28 May

Prothena downgraded to Underperform at BofA after birtamimab fails in clinic

TIPRANKS
·
28 May

Update: Prothena Shares Fall, Stock Downgraded by Multiple Research Firms After Birtamimab Development Discontinued

MT Newswires Live
·
28 May

Prothena Corporation Plc : H.c. Wainwright Cuts Target Price to $14 From $30

THOMSON REUTERS
·
27 May

Prothena Shares Fall After Trial Results Miss, Job Cuts

Dow Jones
·
27 May

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as US Delays EU Tariff Implementation

MT Newswires Live
·
27 May

Prothena Corporation Plc : Oppenheimer Cuts to Perform From Outperform

THOMSON REUTERS
·
27 May

BUZZ-U.S. STOCKS ON THE MOVE-CoreWeave, U.S. Steel, Southwest Airlines

Reuters
·
27 May

Prothena Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
27 May

Chardan Adjusts PT on Prothena to $18 From $40 After Drug Removal From Model, Keeps Buy Rating

MT Newswires Live
·
27 May

Prothena price target lowered to $18 from $40 at Chardan

TIPRANKS
·
27 May

Prothena downgraded to Hold from Buy at Jefferies

TIPRANKS
·
27 May

Oppenheimer downgrades Prothena (PRTA) to a Hold

TIPRANKS
·
27 May

BUZZ-Ireland's Prothena drops as Jefferies downgrades to 'hold' after drug fails trial

Reuters
·
27 May

Prothena Corporation Plc : Jefferies Cuts to Hold From Buy; Cuts Target Price to $6 From $32

THOMSON REUTERS
·
27 May

Prothena Corporation plc Publishes Presentation on Advancements in Life-Saving Therapies for Protein Dysregulation Diseases

Reuters
·
24 May

BRIEF-Prothena Announces Phase 3 Affirm-Al Clinical Trial For Birtamimab In Patients With Al Amyloidosis Did Not Meet Primary Endpoint

Reuters
·
24 May